CN1182862C - Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn - Google Patents
Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn Download PDFInfo
- Publication number
- CN1182862C CN1182862C CNB031051812A CN03105181A CN1182862C CN 1182862 C CN1182862 C CN 1182862C CN B031051812 A CNB031051812 A CN B031051812A CN 03105181 A CN03105181 A CN 03105181A CN 1182862 C CN1182862 C CN 1182862C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- angina pectoris
- medicine preparation
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 15
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 241000218176 Corydalis Species 0.000 claims abstract description 13
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000000706 filtrate Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 241000208340 Araliaceae Species 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 241000180649 Panax notoginseng Species 0.000 claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000004064 recycling Methods 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 206010008479 Chest Pain Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 229910002651 NO3 Inorganic materials 0.000 abstract 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- -1 filtered Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicine preparation for curing coronary heart disease and angina pectoris, which is characterized in that the present invention is prepared from the following medicinal ingredients: red ginseng, milkvetch root, epimedium herb, corydalis tuber, etc. The present invention can be made into tablets, capsules, granules, oral medicinal liquids, etc. and has the functions of benefiting the heart, replenishing Qi, remoistening blood stasis and alleviating pain. In clinic, the total effective rate for curing angina pectoris is 80.0%, the total effective rate for curing EKG is 65.0%, the total effective rate for curing the symptoms of traditional Chinese medicine, such as chest pain, chest distress, palpitation, short breath, neurolysis, hypodynamia, etc., is 90.0%, the withdrawal rate of nitrate medicine is 40.0%, and the decrement rate of nitrate medicine is 80.0%. In clinical observation, no adverse reaction is discovered. The present invention is an ideal medicine for curing coronary heart disease and angina pectoris.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, especially treat coronary heart disease and anginal preparation and preparation method thereof, its dosage form comprises tablet, capsule, granule, oral liquid and syrup thereof.Belong to field of traditional Chinese.
Background technology:
Coronary heart disease is a kind of cardiovascular disease of serious harm human body health, is commonly encountered diseases, frequently-occurring disease clinically.The U.S. has 2,500 ten thousand people to suffer from this disease according to incompletely statistics, and China's Statistical Beijing City coronary heart disease death rate in 1973 is to rise to 62.0/10 ten thousand people in 21.7/10 ten thousand, 1986; Shanghai coronary heart disease death rate in 1974 be 15.7/10 ten thousand, 1984 be 37.4/10 ten thousand people; Guangzhou coronary heart disease death seventies rate is 4.1/10 ten thousand, increases the eighties to 19.8/10 ten thousand people.This shows that the coronary heart disease death rate is growth trend year by year.Therefore be important problem in the medical domain with Chinese medicine to the treatment research and the Prevention Research of coronary heart disease.In recent years, Chinese medicine is being obtained considerable progress in treatment aspect the primary disease, becomes one of the means of the Comprehensive Treatment of coronary heart disease.In view of coronary heart disease is common clinical, frequently-occurring disease, strengthen top priority to its treatment research person that become the clinical position.
The Chinese medicine angina pectoris has long history and rich experience.Advantages such as the effectiveness of the organic conception of the traditional Chinese medical science, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, dynamic equilibrium and Chinese medicine treatment primary disease, innocuousness, persistence, multiformity are suitable for the treatment of complicated and diversified coronary heart disease.Multidirectional research is observed and was confirmed already, is improving symptom, reduces recurrence, and the aspect of improving the quality of living tcm clinical efficacy is definitely obvious.Taking Chinese medicine for a long time and can reside and prevent integrating prevention, treatment, rehabilitation in controlling, is that current treatment coronary heart disease obtains some and breaks through one of most promising method.Therefore, give full play to the advantage of motherland's medical science,, seek and develop effective prescription of treatment coronary heart disease, have important theoretical meaning and use value in conjunction with the modern study achievement.
Technology contents:
Chinese medicine preparation of the present invention is made by the following dosage proportion raw material: Radix Ginseng Rubra 10～25%, the Radix Astragali 18～30%, Herba Epimedii 16～30%, Rhizoma Corydalis 15～30% and Radix Notoginseng 3～10%.
The preparation method of Chinese medicine preparation of the present invention, the technological process that it is characterized in that described preparation is: Radix Ginseng Rubra, Rhizoma Corydalis and Radix Notoginseng are added 50～80% ethanol extraction secondaries, each 3 hours, merge extractive liquid,, filter, filtrate recycling ethanol also is condensed into that relative density is the concentrated solution of 1.20-1.22 in the time of 60 ℃; The Radix Astragali and Herba Epimedii decoct with water secondary, and each 2 hours, merge extractive liquid,, filter, filtrate concentrates, and concentrated solution adds ethanol, make and contain alcohol and reach 50～70%, precipitate with ethanol, cold preservation 24 hours, filter, filtrate recycling ethanol also is condensed into that relative density is the concentrated solution of 1.21-1.23 in the time of 60 ℃, gets above-mentioned two kinds of concentrated solutions and merges, continue to be condensed into thick paste, drying is pulverized, sieve, be and extract dried medicated powder; Or, add 100～600ml distilled water with above-mentioned two kinds of concentrated solutions merging, be the extraction medicinal liquid; Respectively by extracting dried medicated powder or extracting medicinal liquid and make Chinese medicine preparation.
The dosage form of Chinese medicine preparation of the present invention is tablet, capsule, granule, oral liquid or syrup.
Chinese medicine preparation of the present invention also comprises the following dosage proportion raw material in the described raw material: one or more in Radix Salviae Miltiorrhizae 5～10%, Fructus Schisandrae Chinensis 3～10%, Radix Paeoniae Rubra 2～7% and the Radix Curcumae 2～6%.
The purpose of this invention is to provide a kind of Chinese medicine preparation that angina pectoris has obvious curative effects for the treatment of.The Pharmacodynamic test of active extract result of tablet shows in the said preparation: the large and small dosage group of (1) this preparation all obviously alleviates dog acute myocardial ischemia degree (∑-ST) and dwindle ischemia scope (N-ST), its drug action time may persist to after the administration 240 minutes, all obviously dwindles dog acute myocardial infarction area simultaneously.(2) 2h and 4h make serum glutamic oxalacetic transaminase (AST) and serum paraoxonase kinases isozyme (CK-MB), creatine phosphokinase (CK) obviously reduce respectively after the administration of the heavy dose of group of this preparation; 4h obviously reduces serum CK after the small dose group administration.Large and small dosage group all has reduction trend to lactic acid dehydrogenase (LDH).(3) the large and small dosage group of this preparation all obviously increases cardiac output and coronary flow, and its drug action time may persist to 120min after the administration, has the cardiac function of improvement and hemodynamic effect.(4) the large and small dosage group of this preparation all obviously increases left indoor pressure; Heavy dose of group makes+dp/dt
MaxObviously increase, small dose group only has increase trend; Large and small dosage group is all to a dp/dt
MaxThere is not obviously influence.(5) the large and small dosage group of this preparation does not have obvious influence to Peripheral resistance, but heavy dose of group has reduction trend to coronary resistance.(6) the heavy dose of group of this preparation obviously increases the heart output of whenever fighting, and small dose group has increase trend; Large and small dosage group does not all have obvious influence to the work done of left chamber.(7) the large and small dosage group of this preparation all reduces myocardial oxygen consumption.(8) the large and small dosage group of this preparation does not all have obvious influence to blood pressure and heart rate.
Acute toxicity test of the present invention and long term toxicity test result show and do not see overt toxicity reaction.Clinical observation 40 routine coronary disease with angina pectoris, tablet test group 20 examples wherein, matched group (heart nourishing sheet) 20 examples, the result shows, treats 20 routine patient with angina pectoris, curative effect to treat angina pectoris obvious effective rate 45%, total effective rate 80.0%; EKG obvious effective rate 25.0%, total effective rate 65.0%; Tcm symptom obvious effective rate 55%, total effective rate 90.0%; Nitrate esters medicine drug withdrawal rate 40.0% is stopped lapse rate 80.0%, all is better than matched group.Learn to handle ECG curative effect and nitrate esters by statistics and stop the lapse rate test group and be better than matched group, have significant difference (P＜0.05).Clinical observation confirms that this tablet is the safe and effective medicine of treatment angina pectoris.
The specific embodiment:
Using method of the present invention: every day three times, each 3～6 (or 3～6 capsules, or 1～2 bag of granule, or 1～2 oral liquid, or 10～20ml syrup).30 days is a course of treatment.
Embodiment 1:
Get Radix Ginseng Rubra 400g, Radix Astragali 750g, Herba Epimedii 750g, Rhizoma Corydalis 700g, Radix Notoginseng 200g.Radix Ginseng Rubra, Rhizoma Corydalis and Radix Notoginseng are added 60% ethanol extraction secondary, and each 3 hours, merge extractive liquid, filtered, and filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.20-1.22 (60 ℃); The Radix Astragali, Herba Epimedii decoct with water secondary, and each 2 hours, merge extractive liquid,, filter, filtrate concentrates, add ethanol in the concentrated solution and make and contain the alcohol amount and reach 70%, precipitate with ethanol, cold preservation (2～2 ℃) 24 hours is filtered, and filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.21-1.23 (60 ℃).Get above-mentioned two kinds of concentrated solutions and merge, continue to be condensed into thick paste, drying is pulverized, and sieves, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 200ml distilled water, water precipitating (2～2 ℃) 24 hours filters, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 2:
Get Radix Ginseng Rubra 500g, Radix Astragali 700g, Herba Epimedii 650g, Rhizoma Corydalis 450g, Radix Salviae Miltiorrhizae 200g, Radix Curcumae 150g, Radix Notoginseng 150g, Radix Ginseng Rubra, Rhizoma Corydalis, Radix Notoginseng are added 70% ethanol extraction secondary, each 3 hours, merge extractive liquid,, filter, filtrate recycling ethanol also is condensed into the concentrated solution that relative density is 1.20-1.22 (60 ℃); The Radix Astragali, Herba Epimedii, Radix Salviae Miltiorrhizae, Radix Curcumae decoct with water secondary, each 2 hours, merge extractive liquid, filters, and filtrate concentrates, adding ethanol in the concentrated solution makes and contains the alcohol amount and reach 60%, precipitate with ethanol, cold preservation (2～2 ℃) 24 hours is filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.21-1.23 (60 ℃).Get above-mentioned two kinds of concentrated solutions, merge, continue to be condensed into thick paste, drying is pulverized, and sieves, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 300ml distilled water, water precipitating (2～2 ℃) 24 hours filters, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 3:
Get Radix Ginseng Rubra 450g, Radix Paeoniae Rubra 150g, Radix Astragali 550g, Fructus Schisandrae Chinensis 200g, Radix Salviae Miltiorrhizae 200g, Herba Epimedii 500g, Rhizoma Corydalis 500g, Radix Notoginseng 250g, Radix Ginseng Rubra, Fructus Schisandrae Chinensis, Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Radix Notoginseng are added 50% ethanol extraction secondary, each 3 hours, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.20-1.22 (60 ℃); Radix Salviae Miltiorrhizae decoction dregs and Radix Polygoni Ciliinerve, the Radix Astragali, Herba Epimedii decoct with water secondary together, each 2 hours, merge extractive liquid, filters, and filtrate concentrates, adding ethanol in the concentrated solution makes and contains the alcohol amount and reach 50%, precipitate with ethanol, cold preservation (2～2 ℃) 24 hours is filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.21-1.23 (60 ℃).Get above-mentioned two kinds of concentrated solutions and merge, continue to be condensed into thick paste, drying is pulverized, and sieves, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 600ml distilled water, water precipitating (2～2 ℃) 24 hours filters, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 4:
Get Radix Ginseng Rubra 350g, Radix Salviae Miltiorrhizae 200g, Fructus Schisandrae Chinensis 100g, Radix Astragali 600g, Radix Curcumae 100g, Herba Epimedii 600g, Radix Paeoniae Rubra 100g, Rhizoma Corydalis 600g, Radix Notoginseng 150g, Radix Ginseng Rubra, Radix Salviae Miltiorrhizae, Rhizoma Corydalis, Radix Notoginseng are added 60% ethanol extraction secondary, each 3 hours, filter, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.20-1.22 (60 ℃); Radix Salviae Miltiorrhizae decoction dregs and Fructus Schisandrae Chinensis, the Radix Astragali, Radix Curcumae, Herba Epimedii, Radix Paeoniae Rubra decoct with water secondary together, each 2 hours, merge extractive liquid, filters, and filtrate concentrates, adding ethanol in the concentrated solution makes and contains the alcohol amount and reach 60%, precipitate with ethanol, cold preservation (2～2 ℃) 24 hours is filtered, filtrate recycling ethanol, and be condensed into the concentrated solution that relative density is 1.21-1.23 (60 ℃).Get above-mentioned two kinds of concentrated solutions and merge, continue to be condensed into thick paste, drying is pulverized, and sieves, and is the dried medicated powder of extraction of the present invention; Or get above-mentioned two kinds of concentrated solutions merging, and adding the 600ml distilled water, water precipitating (2～2 ℃) 24 hours filters, and filtrate is extraction medicinal liquid of the present invention.
Embodiment 5: tablet
To add 120g starch, 20g microcrystalline Cellulose in the dried medicated powder of any extraction in the various embodiments described above,, mixing is granulated, and oven dry is sieved, and adds the 1.5g magnesium stearate, and mixing is pressed into 1000, is tablet of the present invention.
Embodiment 6: capsule
To add 180g starch in the dried medicated powder of any extraction in the various embodiments described above, mixing is granulated, and sieves, and adorns 1000 capsules, is capsule of the present invention.
Embodiment 7: granule
Will be in the various embodiments described above any one extracts and adds cane sugar powder 400g in the dried medicated powder, and dextrin 800g granulates, and granulate sieves, and makes the 2000g granule, granule of the present invention.
Embodiment 8: oral liquid
Will be in above-mentioned each experimental example any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, the 400ml distilled water, sterilization, the 1000ml oral liquid is made in fill, oral liquid of the present invention.
Embodiment 9: syrup
Will be in the foregoing description any one extracts and adds 0.3% sodium benzoate in the medicinal liquid, adds sucrose 300g, xanthan gum 100g, makes the 1000ml syrup, syrup of the present invention.
According to prescription of the present invention, can also make the preparation of other dosage forms such as suspensoid, injection, drop pill.
Coronary heart disease, angina pectoris belong to the traditional Chinese medical science " thoracic obstruction, pained " category, and its cause of disease can have innate deficiency, and is worn with age, improper diet and overtiredness, and internal injury caused by excess of seven emotions, prolonged illness consumption wound etc., main pathogenesis is deficiency of vital QI, unable fortune blood, the resistance of blood stasis numbness, heart arteries and veins is obstructed.Preparation of the present invention adopts beneficial heart QI invigorating at pathogenesis one blood stasis due to qi deficiency of coronary heart disease, anginal deficiency in origin and excess in superficiality, the method treating both the principal and secondary aspects of a disease of blood circulation promoting and blood stasis dispelling.Be used for angina pectoris blood stasis due to qi deficiency disease, disease is seen chest pain, and is uncomfortable in chest, shortness of breath and palpitation, and spiritlessness and weakness, spontaneous perspiration, color of the lip is purple dark, light red tongue purple, the puckery grade of deficient and weak pulse disease.Method is consolidated it with vital energy benefiting and the kidney invigorating, removes its mark with blood circulation promoting and blood stasis dispelling.Gas foot blood contains then that arteries and veins is filled with power, and sering is unobstructed, and QI and blood is moistened the work recovery of supporting the five internal organs extremity, thereby makes transference cure, and disease must heal.
Technology of the present invention is simple, and clinical efficacy is better, and very big value of exploiting and utilizing is arranged.
Claims (4)
1. Chinese medicine preparation for the treatment of angina pectoris is characterized in that described Chinese medicine preparation made by the following dosage proportion raw material: Radix Ginseng Rubra 10～25%, the Radix Astragali 18～30%, Herba Epimedii 16～30%, Rhizoma Corydalis 15～30% and Radix Notoginseng 3～10%.
2. the preparation method of the described Chinese medicine preparation of claim 1, the technological process that it is characterized in that described preparation is: Radix Ginseng Rubra, Rhizoma Corydalis and Radix Notoginseng are added 50～80% ethanol extraction secondaries, each 3 hours, merge extractive liquid,, filter, filtrate recycling ethanol also is condensed into that relative density is the concentrated solution of 1.20-1.22 in the time of 60 ℃; The Radix Astragali and Herba Epimedii decoct with water secondary, and each 2 hours, merge extractive liquid,, filter, filtrate concentrates, and concentrated solution adds ethanol, make and contain alcohol and reach 50～70%, precipitate with ethanol, cold preservation 24 hours, filter, filtrate recycling ethanol also is condensed into that relative density is the concentrated solution of 1.21-1.23 in the time of 60 ℃, gets above-mentioned two kinds of concentrated solutions and merges, continue to be condensed into thick paste, drying is pulverized, sieve, be and extract dried medicated powder; Or, add 100～600ml distilled water with above-mentioned two kinds of concentrated solutions merging, be the extraction medicinal liquid; Respectively by extracting dried medicated powder or extracting medicinal liquid and make Chinese medicine preparation.
3. the described Chinese medicine preparation of claim 1 is characterized in that dosage form is tablet, capsule, granule, oral liquid or syrup.
4. the described a kind of Chinese medicine preparation for the treatment of angina pectoris of claim 1 is characterized in that also comprising in the described raw material following dosage proportion raw material: one or more in Radix Salviae Miltiorrhizae 5～10%, Fructus Schisandrae Chinensis 3～10%, Radix Paeoniae Rubra 2～7% and the Radix Curcumae 2～6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031051812A CN1182862C (en) | 2003-03-06 | 2003-03-06 | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031051812A CN1182862C (en) | 2003-03-06 | 2003-03-06 | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1432393A CN1432393A (en) | 2003-07-30 |
| CN1182862C true CN1182862C (en) | 2005-01-05 |
Family
ID=27634063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031051812A Expired - Lifetime CN1182862C (en) | 2003-03-06 | 2003-03-06 | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1182862C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1297290C (en) * | 2005-05-23 | 2007-01-31 | 刘德胜 | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method |
| CN101926845A (en) * | 2010-08-10 | 2010-12-29 | 邓家刚 | Application of medicinal composition in preparation of medicament for treating coronary heart disease |
| CN103202883A (en) * | 2013-03-15 | 2013-07-17 | 洛阳市第一中医院 | Component of capsule for treating angina caused by coronary heart disease and method for preparing component |
| CN104667174B (en) * | 2015-02-03 | 2018-02-06 | 辽宁中医药大学 | A kind of iquid capsule for treating coronary heart disease syndrome of yang deficiency and blood stasis and preparation method thereof |
-
2003
- 2003-03-06 CN CNB031051812A patent/CN1182862C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1432393A (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN102161961B (en) | Health-care wine and preparation method thereof | |
| CN1305483C (en) | Heart failure regulating Chinese medicine | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN103372135B (en) | Chinese medicinal composition treating cardiovascular and cerebrovascular diseases caused by heart-kidney imbalance | |
| CN1895547B (en) | Medicine for treating diabetes and its preparation | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN100337660C (en) | Hypertension treating Chinese medicine composition | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN102018852B (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN101234170A (en) | Sanweishengmai injection and preparation thereof | |
| CN102614474A (en) | Traditional Chinese medicine for treating coronary heart disease and preparation method thereof | |
| CN103006989A (en) | Medical composition for treating diabetic nephropathy | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN102228596B (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN101455789A (en) | Traditional Chinese medicine preparation with blood-sugar reduction and diuresis function and preparation method thereof | |
| CN101104033A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Ling Peixue Document name: Notification to Pay the Fees |
|
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ling Peixue Inventor after: Zhang Ling Inventor after: Shi Yanzeng Inventor after: Shang Lixia Inventor before: Ling Peixue Inventor before: Zhang Ling Inventor before: Shi Yanzeng Inventor before: Qu Yanwei Inventor before: Shang Lixia Inventor before: Hu Qingwen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LING PEIXUE ZHANG LING SHI YANZENG QU YANWEI SHANG LIXIA HU QINGWEN TO: LING PEIXUE ZHANG LING SHI YANZENG SHANG LIXIA |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 250101 989 Xinjie street, Ji'nan high tech Zone, Shandong Patentee after: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES Address before: 250014 No. 264 Shanda Road, Jinan City, Shandong Province Patentee before: Ling Peixue |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050105 |